Wavelength Pharmaceuticals

Company Overview

Snapshot

Founded in January 1987, Wavelength Pharmaceuticals operates with 51–200 employees. The company was acquired by SEQENS in December 2021, marking a significant exit event in its trajectory.

Business overview

Wavelength Pharmaceuticals specializes in the development and manufacturing of active pharmaceutical ingredients (APIs) and select finished dosage forms. The company focuses on differentiated products that necessitate sophisticated manufacturing processes, offering comprehensive technical and regulatory support throughout the product lifecycle. Its core strengths lie in complex chemistry, innovative process development, crystalline forms, and particle design, providing customized API CDMO services from preclinical to commercial scales. Wavelength Pharmaceuticals operates within the Health Tech & Life Sciences sector, specifically targeting the pharmaceutical industry with its B2B business model.

Strategic signal

In July 2022, Wavelength Pharmaceuticals, in partnership with On Demand Pharmaceuticals, was awarded a grant from the US-Israel Binational Industrial Research & Development (BIRD) Foundation. This $1M investment aims to advance on-demand, point-of-care medicine manufacturing, leveraging both companies' capabilities to strengthen the supply of essential medicines and their ingredients. This collaboration signals a strategic focus on mitigating supply chain risks and addressing drug shortages, demonstrating the company's commitment to innovation and market responsiveness even after its acquisition.

Company Intelligence Q&A

When was Wavelength Pharmaceuticals acquired?

Wavelength Pharmaceuticals was acquired by SEQENS in December 2021.

What was the nature of the partnership between Wavelength Pharmaceuticals and Tikun-Olam Cannbit?

In August 2021, Wavelength Pharmaceuticals partnered with Tikun-Olam Cannbit to jointly develop, manufacture, and market cannabis-based raw materials for the pharmaceutical industry, targeting the global pharmaceutical market.

What strategic acquisition did Wavelength Pharmaceuticals make in February 2021?

In February 2021, Wavelength Pharmaceuticals acquired Vanamali Organics to strengthen its global supply chain.

How did Wavelength Pharmaceuticals respond to the COVID-19 pandemic in April 2020?

In April 2020, Wavelength Pharmaceuticals expanded its production of Active Pharmaceutical Ingredients (APIs) for medications used to treat critically ill COVID-19 patients and launched new API CDMO services.

What was the initial acquisition that led to the formation of Wavelength Pharmaceuticals?

In November 2017, SK Capital Partners acquired Perrigo's Israeli API unit Chemagis for $110 million, subsequently renaming it Wavelength Pharmaceuticals.